To meet criteria, the application of poly(ADP-ribose) polymerase (PARP) inhibitors alone or in combination with chemotherapeutic drugs/agents seems to be an attractive neoadjuvant option for patients carrying these breast cancer subtypes. This evidence concerns the gene PARP1 and breast cancer.